



GUIDELINE



ALTERNATIVE MASS DRUG ADMINISTRATION
REGIMENS TO ELIMINATE LYMPHATIC FILARIASIS



World Health
Organization

GUIDELINE

Alternative mass drug administration
regimens to eliminate lymphatic filariasis

Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis

ISBN 978-92-4-155016-1

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Guideline: Alternative mass drug administration regimens to eliminate lymphatic filariasis. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

WHO/HTM/NTD/PCT/2017.07

Contents

Abbreviations.....	v
Glossary.....	vi
Acknowledgements.....	xii
Executive summary.....	xv
1. Background.....	1
1.1. Objective of the guideline.....	4
1.2. Guiding principles.....	6
1.3. Target audience.....	6
1.4. Guideline questions.....	6
2. Methodology and process used to develop the guideline.....	9
2.1. WHO guideline development process.....	9
2.2. Systematic review.....	10
2.3. Guideline development group.....	10
2.4. Conflicts of interest.....	11
2.5. Roles.....	11
2.6. Development of the guideline.....	11
2.7. Formulation of recommendations.....	12
2.8. Target population preferences and views.....	13
3. Recommendations for countries using DA MDA to eliminate lymphatic filariasis.....	14
3.1. Comparison of annual IDA versus annual DA.....	14
3.2. Comparison of biannual DA versus annual DA.....	25
4. Recommendations for countries co-endemic for onchocerciasis using IA MDA to eliminate lymphatic filariasis.....	31
4.1. Comparison of annual IDA versus annual IA.....	31
4.2. Comparison of biannual IA versus annual IA.....	35
4.3. Comparison of biannual albendazole versus annual albendazole.....	39
5. Dissemination, implementation, and monitoring and evaluation of the guideline.....	44
5.1. Dissemination.....	44
5.2. Implementation.....	44
5.3. Monitoring and evaluation.....	45
5.4. Guideline updates.....	46
References.....	47

Available separately:

Annex 1. GRADE tables

Annex 2. Systematic review report

Annex 3. Members of the guideline development group

Annex 4. Declaration of interests table

Abbreviations

AE	adverse event
<i>Brugia</i> spp.	<i>Brugia malayi</i> and <i>Brugia timori</i> species
CFA	circulating filarial antigen
DA	diethylcarbamazine (citrate) plus albendazole
FTS	Filaria Test Strip (Alere, Scarborough, ME, USA)
GPELF	Global Programme to Eliminate Lymphatic Filariasis
GRADE	Grading of Recommendations Assessment, Development and Evaluation
IA	ivermectin plus albendazole
ICT	immunochromatographic test (BinaxNOW Filariasis ICT, Alere, USA)
IDA	ivermectin plus diethylcarbamazine (citrate) plus albendazole
IgG4	IgG4 antibody to BmR1 antigen of <i>Brugia</i> species
IU	implementation unit
LF	lymphatic filariasis
MDA	mass drug administration
PICO	population, intervention, comparator and outcome
pre-TAS	pre-transmission assessment survey
RCT	randomized controlled trial
SAE	serious adverse event
TAS	transmission assessment survey
WHO	World Health Organization

Glossary

The definitions given below apply to the terms as used in this guideline. They may have different meanings in other contexts and WHO documents. An asterisk (*) next to terms denotes definition of outcomes assessed in the development of recommendations.

adverse event (AE) following mass drug administration (MDA)*

A medical incident occurring after mass drug administration that is suspected to be but is not necessarily caused by the medicines used in the intervention. Some AEs, after investigation, may be found to have been caused by the medicine and are also referred to as adverse drug reactions or side-effects.

Note: AEs are often categorized by severity in clinical studies. While the grade of severity may vary, the following classifications were used for the outcomes reviewed in these comparisons:

- Grade 1 – a mild adverse event that does not interfere with work or school;
- Grade 2 – a moderate adverse event that interferes with work or school for at least 1 day;
- Grade 3 – a severe and undesirable adverse event that interferes with the activities of daily living and requires medical assessment;
- Grade 4 – a potentially life-threatening or disabling adverse event that requires medical evaluation and a serious adverse event report; and
- Grade 5 – a catastrophic adverse event that causes death.

During the process of formulating the recommendations, the following designations were given to the outcomes of adverse event and serious adverse event:

- Critical – serious adverse events (Grade 4 and 5), adverse events (Grade 3 and 4) and adverse events (Grade 2 to 4) in communities with no prior MDA;
- Important – adverse events (Grade 2 to 4) among microfilaraemic persons, any adverse events in microfilaraemic persons and adverse events (Grade 2); and
- Not important – any adverse event not addressed above.

antibody

A protein produced by the human immune system in response to a foreign substance (antigen) to fight off infection. An antibody reacts specifically with the antigen that triggered its formation and its function

预览已结束，完整报告链接和二

<https://www.yunbaogao.cn/report/index/report?rep>